Sökning: "somatostatin receptors"
Visar resultat 36 - 40 av 44 avhandlingar innehållade orden somatostatin receptors.
36. Atopic dermatitis : aspects of defence defects
Sammanfattning : Atopic dermatitis (AD) is an inflammatory skin disease, typically with a chronic relapsing course and a defective skin barrier function. Recently, mutations of the skin barrier gene encoding filaggrin have been reported in a portion of the patients. In this thesis some aspects of defence defects in AD were studied. LÄS MER
37. Comparatative studies on the IGF system in vertebrates : studies in rats, and in bony, cartilaginous, and jawless fish
Sammanfattning : Numerous studies have shown the importance of insulin-like growth factors (IGFs) for cellular growth, differentiation and metabolism in mammalian vertebrates. The mammalian IGF system, consists of IGF-1 and IGF-2, the IGF binding proteins (IGFBPs), and the type1 and type 2 IGF receptors. LÄS MER
38. Pharmacokinetics and dosimetry of radiolabelled octreotide for tumour therapy
Sammanfattning : Somatostatin (SS) receptors (sstr) are usually highly expressed on neuroendocrine (NE) tumours. The radiolabelled SS analogue 111In-DTPA-D-Phe1-octreotide is today widely used to scintigraphically visualise NE tumours, and high 111In activity concentrations are obtained in tumour vs. normal tissues. LÄS MER
39. Evolution of the G protein-coupled receptor signaling system : Genomic and phylogenetic analyses
Sammanfattning : Signal transduction pathways mediated by G protein-coupled receptors (GPCRs) and their intracellular coupling partners, the heterotrimeric G proteins, are crucial for several physiological functions in eukaryotes, including humans. This thesis describes a broad genomic survey and extensive comparative phylogenetic analysis of GPCR and G protein families from a wide selection of eukaryotes. LÄS MER
40. Targeted radionuclide therapy for patients with neuroendocrine tumours with focus on normal tissue response in 177-Lu-DOTATATE treatment
Sammanfattning : Targeted radionuclide therapy with 177Lu-DOTATATE for patients with neuroendocrine tumours utilises the frequent overexpressing of somatostatin receptors on the tumour cells. This treatment modality has demonstrated valuable patient benefits and is well tolerated. However, renal and bone marrow toxicity can become dose limiting and persisting. LÄS MER